Fig. 2.

IL-1β treatment induces Trim63 (MuRF1) and Fbxo32 (atrogin 1) gene expression and reduces slow and fast myosin heavy chain (MyHC) in C2C12 myotubes. a C2C12 cells were differentiated for 8 days and treated with human recombinant IL-1β (10 ng/ml) for 72 h. Dexamethasone (10 μM/ml) treatment was used as atrophy control. Western blot analysis with anti-myosin heavy chain (MyHC) slow and anti-MyHC-fast antibody. n = 3. GAPDH was used as loading control. b C2C12 cells were differentiated for 8 days and treated with human recombinant IL-1β (10 ng/ml) for 24 h. Dexamethasone (10 μM/ml) treatment was used as atrophy control. qRT-PCR analysis of myosin heavy chain (Myh) 2, Myh4, and Myh7 expression. mRNA expression was normalized to Gapdh. Data are presented as mean ± SEM. n = 3. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. c C2C12 cells were differentiated for 8 days and treated with human recombinant IL-1β (10 ng/ml) for 2 h. Dexamethasone (10 μM/ml) treatment was used as atrophy control. qRT-PCR analysis of Trim63 (MuRF1) and Fbxo32 (atrogin 1) expression. mRNA expression was normalized to Gapdh. Data are presented as mean ± SEM. n = 3. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001